FI103887B1 - Menetelmä terapeuttisesti käyttökelpoisten imidatsolyylimetyyli-pyridiinien valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten imidatsolyylimetyyli-pyridiinien valmistamiseksi

Info

Publication number
FI103887B1
FI103887B1 FI924233A FI924233A FI103887B1 FI 103887 B1 FI103887 B1 FI 103887B1 FI 924233 A FI924233 A FI 924233A FI 924233 A FI924233 A FI 924233A FI 103887 B1 FI103887 B1 FI 103887B1
Authority
FI
Finland
Prior art keywords
carbon atoms
alkyl
imidazolylmethyl
pyridines
preparation
Prior art date
Application number
FI924233A
Other languages
English (en)
Swedish (sv)
Other versions
FI103887B (fi
FI924233A (fi
FI924233A0 (fi
Inventor
Rudolf Karl Andreas Giger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of FI924233A0 publication Critical patent/FI924233A0/fi
Publication of FI924233A publication Critical patent/FI924233A/fi
Application granted granted Critical
Publication of FI103887B publication Critical patent/FI103887B/fi
Publication of FI103887B1 publication Critical patent/FI103887B1/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI924233A 1991-09-23 1992-09-21 Menetelmä terapeuttisesti käyttökelpoisten imidatsolyylimetyyli-pyridiinien valmistamiseksi FI103887B1 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4131584A DE4131584A1 (de) 1991-09-23 1991-09-23 Imidazolylmethyl-pyridine, ihre herstellung und anwendung als pharmazeutika

Publications (4)

Publication Number Publication Date
FI924233A0 FI924233A0 (fi) 1992-09-21
FI924233A FI924233A (fi) 1993-03-24
FI103887B FI103887B (fi) 1999-10-15
FI103887B1 true FI103887B1 (fi) 1999-10-15

Family

ID=6441240

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924233A FI103887B1 (fi) 1991-09-23 1992-09-21 Menetelmä terapeuttisesti käyttökelpoisten imidatsolyylimetyyli-pyridiinien valmistamiseksi

Country Status (24)

Country Link
EP (1) EP0534904B1 (fi)
JP (1) JP2568356B2 (fi)
KR (1) KR100254085B1 (fi)
AT (1) ATE144509T1 (fi)
AU (1) AU650569B2 (fi)
CA (1) CA2078700C (fi)
CZ (1) CZ281675B6 (fi)
DE (2) DE4131584A1 (fi)
DK (1) DK0534904T3 (fi)
ES (1) ES2092666T3 (fi)
FI (1) FI103887B1 (fi)
GR (1) GR3021444T3 (fi)
HU (2) HUT61993A (fi)
IL (1) IL103229A (fi)
MX (1) MX9205365A (fi)
MY (1) MY110450A (fi)
NO (1) NO301162B1 (fi)
NZ (1) NZ244420A (fi)
RO (1) RO109337B1 (fi)
RU (1) RU2058312C1 (fi)
SG (1) SG43079A1 (fi)
SK (1) SK279224B6 (fi)
TW (1) TW222630B (fi)
ZA (1) ZA927279B (fi)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10165349A (ja) * 1996-12-06 1998-06-23 Matsushita Electric Ind Co Ltd 食器洗浄機
DE10000161A1 (de) * 2000-01-06 2001-07-19 Boehringer Ingelheim Pharma Verfahren zur Identifikation eines Proteaseinhibitors
GB0009037D0 (en) * 2000-04-13 2000-05-31 Novartis Ag Organic compounds
EP1919477B1 (en) * 2005-07-29 2012-07-11 Vanda Pharmaceuticals Inc. Use of [2-(2-methylimidazol-1-yl)methyl]pyridine for treating sleep disorders
AU2007214487A1 (en) * 2006-02-13 2007-08-23 Vanda Pharmaceuticals, Inc. Stable dosage formulations of imidazolylalkyl-pyridines
WO2009097416A1 (en) * 2008-01-29 2009-08-06 Vanda Pharmaceuticals, Inc. Imidazolylalkyl- pyridines as dbh inhibitors
CA2740873C (en) 2008-10-17 2019-09-10 Wisconsin Alumni Research Foundation Method of making biologically active alpha-beta peptides
WO2012052540A1 (en) * 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
JP2020520952A (ja) * 2017-05-22 2020-07-16 トーリー パインズ インスティテュート フォー モレキュラー スタディーズTorrey Pines Institute For Molecular Studies 組成物、使用方法、及び治療方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2862340D1 (en) * 1978-02-01 1983-11-24 Wellcome Found Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof
GB2028317B (en) * 1978-08-15 1982-11-10 Pfizer Ltd 2-(imidazol-1-ylmethyl)-pyridine and -quinoline thromboxane synthetase inhibitors
US4634711A (en) * 1985-08-02 1987-01-06 Smithkline Beckman Corporation Pyridylalkyl imidazole-2-thiols
DE3811574A1 (de) * 1988-03-31 1989-10-19 Schering Ag N-substituierte imidazole, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln

Also Published As

Publication number Publication date
NO301162B1 (no) 1997-09-22
AU650569B2 (en) 1994-06-23
FI103887B (fi) 1999-10-15
JP2568356B2 (ja) 1997-01-08
MY110450A (en) 1998-05-30
EP0534904A1 (de) 1993-03-31
HUT61993A (en) 1993-03-29
ATE144509T1 (de) 1996-11-15
ZA927279B (en) 1994-03-23
IL103229A0 (en) 1993-02-21
CA2078700C (en) 2005-09-13
FI924233A (fi) 1993-03-24
IL103229A (en) 1996-09-12
JPH05194491A (ja) 1993-08-03
NZ244420A (en) 1995-07-26
HU9202886D0 (en) 1992-11-30
DK0534904T3 (da) 1996-11-18
CZ289692A3 (en) 1993-04-14
DE4131584A1 (de) 1993-03-25
CZ281675B6 (cs) 1996-12-11
KR100254085B1 (ko) 2000-09-01
GR3021444T3 (en) 1997-01-31
SG43079A1 (en) 1997-10-17
SK289692A3 (en) 1998-08-05
AU2522692A (en) 1993-03-25
DE59207425D1 (de) 1996-11-28
FI924233A0 (fi) 1992-09-21
NO923653D0 (no) 1992-09-21
MX9205365A (es) 1993-03-01
RU2058312C1 (ru) 1996-04-20
ES2092666T3 (es) 1996-12-01
RO109337B1 (ro) 1995-01-30
CA2078700A1 (en) 1993-03-24
KR930006003A (ko) 1993-04-20
EP0534904B1 (de) 1996-10-23
NO923653L (no) 1993-03-24
SK279224B6 (sk) 1998-08-05
HU211261A9 (en) 1995-11-28
TW222630B (fi) 1994-04-21

Similar Documents

Publication Publication Date Title
EP0239445A3 (en) 1,2,5,6-tetrahydropyridine-3-carboxaldehyde oxime derivatives, process for their preparation, compositions containing them and their use as medicines
FI103887B (fi) Menetelmä terapeuttisesti käyttökelpoisten imidatsolyylimetyyli-pyridiinien valmistamiseksi
MX12708A (es) Derivados de oxima de 1,2,5,6-tetrahidropiridina yprocedimiento para su preparacion
JPS6468356A (en) Novel 1,2,5,6-tetrahydropyridine-3-carboxaldehydro oxime derivatives, use as drug and composition

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

MM Patent lapsed